JP2013515049A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515049A5
JP2013515049A5 JP2012545493A JP2012545493A JP2013515049A5 JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5 JP 2012545493 A JP2012545493 A JP 2012545493A JP 2012545493 A JP2012545493 A JP 2012545493A JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5
Authority
JP
Japan
Prior art keywords
composition
klh
concentration
present
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545493A
Other languages
English (en)
Japanese (ja)
Other versions
JP6007105B2 (ja
JP2013515049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/055674 external-priority patent/WO2011077309A2/en
Publication of JP2013515049A publication Critical patent/JP2013515049A/ja
Publication of JP2013515049A5 publication Critical patent/JP2013515049A5/ja
Application granted granted Critical
Publication of JP6007105B2 publication Critical patent/JP6007105B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545493A 2009-12-22 2010-12-08 ワクチン組成物 Expired - Fee Related JP6007105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105966A Division JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Publications (3)

Publication Number Publication Date
JP2013515049A JP2013515049A (ja) 2013-05-02
JP2013515049A5 true JP2013515049A5 (enExample) 2014-01-30
JP6007105B2 JP6007105B2 (ja) 2016-10-12

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012545493A Expired - Fee Related JP6007105B2 (ja) 2009-12-22 2010-12-08 ワクチン組成物
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Country Status (13)

Country Link
US (3) US20130034573A1 (enExample)
EP (2) EP2515934B1 (enExample)
JP (2) JP6007105B2 (enExample)
KR (1) KR20120120185A (enExample)
CN (2) CN107412754A (enExample)
AU (1) AU2010334428B2 (enExample)
CA (1) CA2785585A1 (enExample)
IL (1) IL220308A0 (enExample)
MX (1) MX337070B (enExample)
NZ (2) NZ629256A (enExample)
RU (1) RU2581020C2 (enExample)
SG (2) SG181628A1 (enExample)
WO (1) WO2011077309A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2536399T (lt) * 2010-02-21 2020-03-10 Bayer Healthcare Llc Biomolekulių aktyvinimo ir konjugavimo būdas
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN112088017B (zh) * 2018-07-19 2023-11-21 赫利世弥斯株式会社 用于裸脱氧核糖核酸基因疗法的经冷冻干燥的药剂学组合物
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (enExample) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69821246T2 (de) * 1997-07-31 2004-11-04 Metra Biosystems, Inc., Mountain View Testverfahren für collagenpeptid
DE69840508D1 (de) * 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥c反応性タンパク質組成物
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
DE60334460D1 (de) * 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
MXPA05014155A (es) * 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
AU2006284248B2 (en) * 2005-05-24 2010-10-07 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFalpha and a carrier protein
DK1940461T3 (da) * 2005-11-02 2014-03-31 Univ Duke Samtidig kemoterapi og immunterapi
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations

Similar Documents

Publication Publication Date Title
JP2013531679A5 (enExample)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2021512881A5 (enExample)
JP2016534052A5 (enExample)
JP2021046436A (ja) ペプチド模倣大環状分子およびその製剤
RU2011127913A (ru) Составы, содержащие антитела
US11759497B2 (en) Daptomycin formulations
KR20200097295A (ko) 분지형 링커를 갖는 튜불리신 유사체의 접합체
JP2011173914A5 (enExample)
JP2021504372A5 (enExample)
KR20210122318A (ko) 비스-링키지를 사용한 세포독성 약물의 접합
IL294463A (en) Methods for treating or preventing eye conditions
KR20020026558A (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
JP2017514868A5 (enExample)
JP2024508762A5 (enExample)
RS54083B1 (sr) Derivati metastina i njihova upotreba
RU2013128361A (ru) Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota
JP7126270B2 (ja) Npraアゴニスト、組成物およびその使用
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
CN111148510A (zh) 用于治疗性蛋白质的冻干药物配制品的方法
JP2007534698A5 (enExample)
JP2021519790A5 (enExample)
JP6580581B2 (ja) 注射用医薬組成物
JP2023553538A5 (enExample)
RU2018129077A (ru) Стабильная фармацевтическая композиция